<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33308429</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>397</Volume><Issue>10268</Issue><PubDate><Year>2021</Year><Month>Jan</Month><Day>02</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials.</ArticleTitle><Pagination><StartPage>39</StartPage><EndPage>50</EndPage><MedlinePgn>39-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(20)32541-1</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0140-6736(20)32541-1</ELocationID><Abstract><AbstractText Label="BACKGROUND">Two novel type 2 oral poliovirus vaccine (OPV2) candidates, novel OPV2-c1 and novel OPV2-c2, designed to be more genetically stable than the licensed Sabin monovalent OPV2, have been developed to respond to ongoing polio outbreaks due to circulating vaccine-derived type 2 polioviruses.</AbstractText><AbstractText Label="METHODS">We did two randomised studies at two centres in Belgium. The first was a phase 4 historical control study of monovalent OPV2 in Antwerp, done before global withdrawal of OPV2, and the second was a phase 2 study in Antwerp and Ghent with novel OPV2-c1 and novel OPV2-c2. Eligible participants were healthy adults aged 18-50 years with documented history of at least three polio vaccinations, including OPV in the phase 4 study and either OPV or inactivated poliovirus vaccine (IPV) in the novel OPV2 phase 2 study, with no dose within 12 months of study start. In the historical control trial, participants were randomly assigned to either one dose or two doses of monovalent OPV2. In the novel OPV2 trial, participants with previous OPV vaccinations were randomly assigned to either one or two doses of novel OPV2-c1 or to one or two doses of novel OPV2-c2. IPV-vaccinated participants were randomly assigned to receive two doses of either novel OPV2-c1, novel OPV2-c2, or placebo. Vaccine administrators were unmasked to treatment; medical staff performing safety and reactogenicity assessments or blood draws for immunogenicity assessments were masked. Participants received the first vaccine dose on day 0, and a second dose on day 28 if assigned to receive a second dose. Primary objectives were assessments and comparisons of safety up to 28 days after each dose, including solicited adverse events and serious adverse events, and immunogenicity (seroprotection rates on day 28 after the first vaccine dose) between monovalent OPV2 and the two novel OPV2 candidates. Primary immunogenicity analyses were done in the per-protocol population. Safety was assessed in the total vaccinated population-ie, all participants who received at least one dose of their assigned vaccine. The phase 4 control study is registered with EudraCT (2015-003325-33) and the phase 2 novel OPV2 study is registered with EudraCT (2018-001684-22) and ClinicalTrials.gov (NCT04544787).</AbstractText><AbstractText Label="FINDINGS">In the historical control study, between Jan 25 and March 18, 2016, 100 volunteers were enrolled and randomly assigned to receive one or two doses of monovalent OPV2 (n=50 in each group). In the novel OPV2 study, between Oct 15, 2018, and Feb 27, 2019, 200 previously OPV-vaccinated volunteers were assigned to the four groups to receive one or two doses of novel OPV2-c1 or novel OPV2-c2 (n=50 per group); a further 50 participants, previously vaccinated with IPV, were assigned to novel OPV2-c1 (n=17), novel OPV2-c2 (n=16), or placebo (n=17). All participants received the first dose of assigned vaccine or placebo and were included in the total vaccinated population. All vaccines appeared safe; no definitely vaccine-related withdrawals or serious adverse events were reported. After first doses in previously OPV-vaccinated participants, 62 (62%) of 100 monovalent OPV2 recipients, 71 (71%) of 100 recipients of novel OPV2-c1, and 74 (74%) of 100 recipients of novel OPV2-c2 reported solicited systemic adverse events, four (monovalent OPV2), three (novel OPV2-c1), and two (novel OPV2-c2) of which were considered severe. In IPV-vaccinated participants, solicited adverse events occurred in 16 (94%) of 17 who received novel OPV2-c1 (including one severe) and 13 (81%) of 16 who received novel OPV2-c2 (including one severe), compared with 15 (88%) of 17 placebo recipients (including two severe). In previously OPV-vaccinated participants, 286 (97%) of 296 were seropositive at baseline; after one dose, 100% of novel OPV2 vaccinees and 97 (97%) of monovalent OPV2 vaccinees were seropositive.</AbstractText><AbstractText Label="INTERPRETATION">Novel OPV2 candidates were as safe, well tolerated, and immunogenic as monovalent OPV2 in previously OPV-vaccinated and IPV-vaccinated adults. These data supported the further assessment of the vaccine candidates in children and infants.</AbstractText><AbstractText Label="FUNDING">University of Antwerp and Bill &amp; Melinda Gates Foundation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Coster</LastName><ForeName>Ilse</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leroux-Roels</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Center for Vaccinology, Ghent University and Ghent University Hospital, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bandyopadhyay</LastName><ForeName>Ananda S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Bill &amp; Melinda Gates Foundation, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gast</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>PATH, Washington DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Withanage</LastName><ForeName>Kanchanamala</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steenackers</LastName><ForeName>Katie</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Smedt</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aerssens</LastName><ForeName>Annelies</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Vaccinology, Ghent University and Ghent University Hospital, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leroux-Roels</LastName><ForeName>Geert</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Center for Vaccinology, Ghent University and Ghent University Hospital, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oberste</LastName><ForeName>M Steven</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konopka-Anstadt</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weldon</LastName><ForeName>William C</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fix</LastName><ForeName>Alan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>PATH, Washington DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konz</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>PATH, Washington DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wahid</LastName><ForeName>Rahnuma</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>PATH, Washington DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Modlin</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Bill &amp; Melinda Gates Foundation, Seattle, WA, USA; PATH, Washington DC, USA; Dartmouth Geisel School of Medicine, Hanover, NH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clemens</LastName><ForeName>Ralf</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Global Research in Infectious Diseases, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costa Clemens</LastName><ForeName>Sue Ann</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Institute for Global Health, Siena University, Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bachtiar</LastName><ForeName>Novilia S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>PT Bio Farma, Bandung, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium. Electronic address: pierre.vandamme@uantwerpen.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04544787</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D017429">Clinical Trial, Phase IV</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2021 Jan 2;397(10268):2-3. doi: 10.1016/S0140-6736(20)32629-5</RefSource><PMID Version="1">33308426</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001530" MajorTopicYN="N" Type="Geographic">Belgium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="Y">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>14</Day><Hour>9</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33308429</ArticleId><ArticleId IdType="pmc">PMC7811203</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(20)32541-1</ArticleId><ArticleId IdType="pii">S0140-6736(20)32541-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO  Two out of three wild poliovirus strains eradicated. Oct 24, 2019. https://www.who.int/news-room/feature-stories/detail/two-out-of-three-wild-poliovirus-strains-eradicated</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative  Polio this week as of 25 November 2020. Nov 25, 2020. http://polioeradication.org/polio-today/polio-now/this-week/</Citation></Reference><Reference><Citation>Alleman MM, Jorba J, Greene SA. Update on vaccine-derived poliovirus outbreaks - worldwide, July 2019&#x2013;February 2020. MMWR Morb Mortal Wkly Rep. 2020;69:489&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7188410</ArticleId><ArticleId IdType="pubmed">32324719</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Polio. Wkly Epidemiol Rec. 2019;95:249&#x2013;252.</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative  . World Health Organization; Geneva: 2020. Strategy for the response to type 2 circulating vaccine-derived poliovirus 2020&#x2013;2021: an addendum to the Polio Endgame Strategy 2019&#x2013;2023.https://polioeradication.org/wp-content/uploads/2020/04/Strategy-for-the-response-to-type-2-circulating-Vaccine-Derived-Poliovirus-20200406.pdf</Citation></Reference><Reference><Citation>Jorba J, Diop OM, Iber J, Sutter RW, Wassilak SG, Burns CC. Update on vaccine-derived polioviruses - worldwide, January 2015&#x2013;May 2016. MMWR Morb Mortal Wkly Rep. 2016;65:763&#x2013;769.</Citation><ArticleIdList><ArticleId IdType="pubmed">27491079</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh MT, Bujaki E, Dolan PT. Engineering the live-attenuated polio vaccine to prevent reversion to virulence. Cell Host Microbe. 2020;27:736. 51.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566161</ArticleId><ArticleId IdType="pubmed">32330425</ArticleId></ArticleIdList></Reference><Reference><Citation>Konopka-Anstadt JL, Campagnoli R, Vincent A. Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization. NPJ Vaccines. 2020;5:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7083942</ArticleId><ArticleId IdType="pubmed">32218998</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, De Coster I, Bandyopadhyay AS. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. Lancet. 2019;394:148&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6626986</ArticleId><ArticleId IdType="pubmed">31174831</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;ez-Llorens X, Bandyopadhyay AS, Gast C. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. Lancet. 2020 doi: 10.1016/S0140-6736(20)32540-X. published online Dec 9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32540-X</ArticleId><ArticleId IdType="pmc">PMC7811205</ArticleId><ArticleId IdType="pubmed">33308427</ArticleId></ArticleIdList></Reference><Reference><Citation>Weldon WC, Oberste MS, Pallansch MA. Standardized methods for detection of poliovirus antibodies. In: Mart&#xed;n J, editor. Poliovirus: methods in molecular biology. Humana Press; New York: 2016. pp. 145&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">26983734</ArticleId></ArticleIdList></Reference><Reference><Citation>Laassri M, Dragunsky E, Enterline J. Genomic analysis of vaccine-derived poliovirus strains in stool specimens by combination of full-length PCR and oligonucleotide microarray hybridization. J Clin Microbiol. 2005;43:2886&#x2013;2894.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1151934</ArticleId><ArticleId IdType="pubmed">15956413</ArticleId></ArticleIdList></Reference><Reference><Citation>Nauta J. Statistics in clinical vaccine trials. Springer-Verlag; Berlin: 2011. Censored antibody titres and maximum likelihood estimation; pp. 49&#x2013;55.</Citation></Reference><Reference><Citation>Bandyopadhyay AS, Gast C, Brickley EB. A randomized phase 4 study of immunogenicity and safety following monovalent oral type 2 Sabin polio vaccine challenge in IPV-vaccinated children in Lithuania. J Infect Dis. 2020 doi: 10.1093/infdis/jiaa390. published online July 4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa390</ArticleId><ArticleId IdType="pmc">PMC7781454</ArticleId><ArticleId IdType="pubmed">32621741</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern A, Yeh MT, Zinger T. The evolutionary pathway to virulence of an RNA virus. Cell. 2017;169:35&#x2013;46.e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5787669</ArticleId><ArticleId IdType="pubmed">28340348</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt LR, Est&#xed;variz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis. 2014;210(suppl 1):S380&#x2013;S389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10424844</ArticleId><ArticleId IdType="pubmed">25316859</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>